341 related articles for article (PubMed ID: 33491298)
1. Improved outcome of children with relapsed/refractory acute myeloid leukemia by addition of cladribine to re-induction chemotherapy.
Ruan M; Liu LP; Zhang AL; Quan Qi B; Liu F; Liu TF; Liu XM; Chen XJ; Yang WY; Guo Y; Zhang L; Zou Y; Chen YM; Zhu XF
Cancer Med; 2021 Feb; 10(3):956-964. PubMed ID: 33491298
[TBL] [Abstract][Full Text] [Related]
2. Cladribine combined with high doses of arabinoside cytosine, mitoxantrone, and G-CSF (CLAG-M) is a highly effective salvage regimen in patients with refractory and relapsed acute myeloid leukemia of the poor risk: a final report of the Polish Adult Leukemia Group.
Wierzbowska A; Robak T; Pluta A; Wawrzyniak E; Cebula B; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Giebel S; Skotnicki AB; Piatkowska-Jakubas B; Kuliczkowski K; Kiełbiński M; Zawilska K; Kłoczko J; Wrzesień-Kuś A;
Eur J Haematol; 2008 Feb; 80(2):115-26. PubMed ID: 18076637
[TBL] [Abstract][Full Text] [Related]
3. Comparison of clinical remission and survival between CLAG and FLAG induction chemotherapy in patients with refractory or relapsed acute myeloid leukemia: a prospective cohort study.
Bao Y; Zhao J; Li ZZ
Clin Transl Oncol; 2018 Jul; 20(7):870-880. PubMed ID: 29181696
[TBL] [Abstract][Full Text] [Related]
4. Decitabine as epigenetic priming with CLAG induce improved outcome of relapsed or refractory acute myeloid leukemia in children.
Zhang N; Li H; Wang D; Wang Z; Zhu JS; Chen K; Jiang H; Shao JB; Cai C
Clin Epigenetics; 2024 May; 16(1):63. PubMed ID: 38725010
[TBL] [Abstract][Full Text] [Related]
5. Treatment of High-Risk Acute Myeloid Leukemia With Cladribine, Cytarabine, Mitoxantrone, and Granulocyte Colony-Stimulating Factor Then Subsequent Bridging to Myeloablative Allogeneic Hematopoietic Stem Cell Transplantation: A Case Series.
Zhang J; Sun Y; Zhang X; Long B; Lu Y; Li X
Transplant Proc; 2018; 50(1):246-249. PubMed ID: 29407318
[TBL] [Abstract][Full Text] [Related]
6. A multicenter, open, non-comparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, and G-CSF as induction therapy in refractory acute myeloid leukemia - a report of the Polish Adult Leukemia Group (PALG).
Wrzesień-Kuś A; Robak T; Lech-Marańda E; Wierzbowska A; Dmoszyńska A; Kowal M; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S; Maj S; Hellmann A; Skotnicki A; Jedrzejczak W; Kuliczkowski K;
Eur J Haematol; 2003 Sep; 71(3):155-62. PubMed ID: 12930315
[TBL] [Abstract][Full Text] [Related]
7. Efficacy of mitoxantrone-based salvage therapies in relapsed or refractory acute myeloid leukemia in the Mayo Clinic Cancer Center: Analysis of survival after 'CLAG-M' vs. 'MEC'.
Scheckel CJ; Meyer M; Betcher JA; Al-Kali A; Foran J; Palmer J
Leuk Res; 2020 Mar; 90():106300. PubMed ID: 32018118
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of common salvage chemotherapy regimens in patients with refractory or relapsed acute myeloid leukemia: A retrospective cohort study.
Xu J; Lv TT; Zhou XF; Huang Y; Liu DD; Yuan GL
Medicine (Baltimore); 2018 Sep; 97(39):e12102. PubMed ID: 30278488
[TBL] [Abstract][Full Text] [Related]
9. Re-induction with modified CLAG regimen in relapsed or refractory acute myeloid leukemia in children bridging to allogeneic hematopoietic stem cell transplantation.
Zhang N; Shao JB; Li H; Yang JW; Chen K; Zhu JS; Jiang H
World J Pediatr; 2020 Apr; 16(2):152-158. PubMed ID: 31748985
[TBL] [Abstract][Full Text] [Related]
10. Salvage chemotherapy regimens for acute myeloid leukemia: Is one better? Efficacy comparison between CLAG and MEC regimens.
Price SL; Lancet JE; George TJ; Wetzstein GA; List AF; Ho VQ; Fernandez HF; Pinilla-Ibarz J; Kharfan-Dabaja MA; Komrokji RS
Leuk Res; 2011 Mar; 35(3):301-4. PubMed ID: 21109304
[TBL] [Abstract][Full Text] [Related]
11. A multicenter, open, noncomparative, phase II study of the combination of cladribine (2-chlorodeoxyadenosine), cytarabine, granulocyte colony-stimulating factor and mitoxantrone as induction therapy in refractory acute myeloid leukemia: a report of the Polish Adult Leukemia Group.
Wrzesień-Kuś A; Robak T; Wierzbowska A; Lech-Marańda E; Pluta A; Wawrzyniak E; Krawczyńska A; Kuliczkowski K; Mazur G; Kiebiński M; Dmoszyńska A; Wach M; Hellmann A; Baran W; Hołowiecki J; Kyrcz-Krzemień S; Grosicki S;
Ann Hematol; 2005 Sep; 84(9):557-64. PubMed ID: 15856358
[TBL] [Abstract][Full Text] [Related]
12. Analysis of Efficacy and Prognostic Factors of CLAG Treatment in Chinese Patients with Refractory or Relapsed Acute Myeloid Leukemia.
Wang L; Xu J; Tian X; Lv T; Yuan G
Acta Haematol; 2019; 141(1):43-53. PubMed ID: 30517910
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy and safety analysis of the combination of cladribine, cytarabine, granulocyte colonystimulating factor (CLAG) regime in patients with refractory or relapsed acute myeloid leukemia].
Duan MH; Zhang Y; Zhang M; Han X; Zhang Y; Yang C; Feng J; Zhang L; Zhang W; Li J; Tian LP; Zhang Y; Zhou DB
Zhonghua Xue Ye Xue Za Zhi; 2016 Jul; 37(7):571-5. PubMed ID: 27535856
[TBL] [Abstract][Full Text] [Related]
14. Mito-FLAG with Ara-C as bolus versus continuous infusion in recurrent or refractory AML--long-term results of a prospective randomized intergroup study of the East German Study Group Hematology/Oncology (OSHO) and the Study Alliance Leukemia (SAL).
Thiel A; Schetelig J; Pönisch W; Schäfer-Eckart K; Aulitzky W; Peter N; Schulze A; Maschmeyer G; Neugebauer S; Herbst R; Hänel A; Morgner A; Kroschinsky F; Bornhäuser M; Lange T; Wilhelm M; Niederwieser D; Ehninger G; Fiedler F; Hänel M; ;
Ann Oncol; 2015 Jul; 26(7):1434-40. PubMed ID: 25922062
[TBL] [Abstract][Full Text] [Related]
15. A phase 1 study of the antibody-drug conjugate brentuximab vedotin with re-induction chemotherapy in patients with CD30-expressing relapsed/refractory acute myeloid leukemia.
Narayan R; Blonquist TM; Emadi A; Hasserjian RP; Burke M; Lescinskas C; Neuberg DS; Brunner AM; Hobbs G; Hock H; McAfee SL; Chen YB; Attar E; Graubert TA; Bertoli C; Moran JA; Bergeron MK; Foster JE; Ramos AY; Som TT; Vartanian MK; Story JL; McGregor K; Macrae M; Behnan T; Wey MC; Rae J; Preffer FI; Lesho P; Duong VH; Mann ML; Ballen KK; Connolly C; Amrein PC; Fathi AT
Cancer; 2020 Mar; 126(6):1264-1273. PubMed ID: 31860140
[TBL] [Abstract][Full Text] [Related]
16. Infectious complications after intensive chemotherapy with CLAG-M versus 7+3 for AML and other high-grade myeloid neoplasms.
Walti CS; Halpern AB; Xie H; Kiem ES; Chung EL; Schonhoff KG; Huebner EM; Delaney C; Liu C; Pergam SA; Cheng GS; Kimball LE; Leisenring WM; Boeckh M; Walter RB; Hill JA
Leukemia; 2023 Feb; 37(2):298-307. PubMed ID: 36509892
[TBL] [Abstract][Full Text] [Related]
17. Phase I study of cladribine, cytarabine (Ara-C), granulocyte colony stimulating factor (G-CSF) (CLAG Regimen) and simultaneous escalating doses of imatinib mesylate (Gleevec) in relapsed/refractory AML.
Walker AR; Komrokji RS; Ifthikharuddin J; Messina P; Mulford D; Becker M; Friedberg J; Oliva J; Phillips G; Liesveld JL; Abboud C
Leuk Res; 2008 Dec; 32(12):1830-6. PubMed ID: 18571721
[TBL] [Abstract][Full Text] [Related]
18. A Phase II Study of CLAG Regimen Combined With Imatinib Mesylate for Relapsed or Refractory Acute Myeloid Leukemia.
Mirza AS; Lancet JE; Sweet K; Padron E; Pinilla-Ibarz J; Nardelli L; Cubitt C; List AF; Komrokji RS
Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):902-907. PubMed ID: 29030092
[TBL] [Abstract][Full Text] [Related]
19. Comparison of salvage chemotherapy regimens and prognostic significance of minimal residual disease in relapsed/refractory acute myeloid leukemia.
Mushtaq MU; Harrington AM; Chaudhary SG; Michaelis LC; Carlson KB; Abedin S; Runass L; Callander NS; Fallon MJ; Juckett M; Hall AC; Hematti P; Mattison RJ; Atallah EL; Guru Murthy GS
Leuk Lymphoma; 2021 Jan; 62(1):158-166. PubMed ID: 32951486
[TBL] [Abstract][Full Text] [Related]
20. Comparison of cladribine- and fludarabine-based induction chemotherapy in relapsed or refractory acute myeloid leukaemia.
Park H; Youk J; Kim I; Yoon SS; Park S; Lee JO; Bang SM; Koh Y
Ann Hematol; 2016 Oct; 95(11):1777-86. PubMed ID: 27539617
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]